News Sentiment

NTLA sentiment intelligence

Intellia Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 60 Balanced news tone 56 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 15.67 Week of 19 Jun 2026
Weighted tone 60/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

77/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

+29.4% over one week, +24.4% over four weeks, trend active, and near fair-value range.

Latest direct headline Negative

Nasdaq, S&P 500 Futures Edge Lower Ahead Of Fed Week, AI Earnings Test: Why POET, ATOM, OGN, QCOM, NTLA Are In Focus

Market Reaction

Price moving ahead of tone

69/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 77/100 classification
One-week reaction 29.4% Price confirming higher
Trend fit Trend active 24.4% over four weeks
Fair value -18.1% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 26
Neutral 25
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 49
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Market source 10
simplywall.st 7
Stock Titan 6
Intellia Therapeutics 5
Simply Wall Street 4
Stocktwits 3
TradingView 3
The Globe and Mail 2

Event Lens

What the news is about

Classified themes
Market update 26
Earnings 21
Analyst action 4
Regulatory and legal 3
Macro sensitivity 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-56 of 56
Stock Titan Direct company coverage

Intellia (NTLA) director awarded RSUs and stock options in new grant

Intellia Therapeutics director William J. Chase received new equity awards on June 9, 2026, comprising 9,200 restricted stock units and stock options for 13,300 shares at an exercise price of $12.89. The stock options vest fully on the earlier of one year from the grant date or t

Tone
Neutral 50/100
Event
Market update
Published
10 Jun 2026 23:10
Source
Stock Titan